Ascletis Pharma Inc.

Ascletis Pharma Inc., a China‑based biopharma founded in 2013, markets GANOVO and Ritonavir for HCV while advancing a robust pipeline—Phase II ASC22 (HBV/CHB), NASH agents (ASC40/41), oncology (ASC61), pre‑clinical COVID‑19—offering diversified growth.

Headquarters: China (CHN)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 208
HQ: Hangzhou

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
1672	Ascletis Pharma Inc. Cap: 13.6B	EQUITY	HKG	HKD	KYG0520K1094	Active	📈